Symptomatic Hyperammonemia With Erwinia chrysanthemi–derived Asparaginase in Pediatric Leukemia Patients

Nathan Gossai(University of Minnesota Children's Hospital), Bruce Bostrom(Minnesota West Community & Technical College), Michael Richards(Max Planck Institute for Solar System Research), Yoav H. Messinger(Children’s Minnesota - St. Paul Hospital), Joanna L. Perkins(Children’s Minnesota - St. Paul Hospital), Sara Gernbacher(Children’s Minnesota - St. Paul Hospital), L.H. Boman(Children’s Minnesota - St. Paul Hospital)
Journal of Pediatric Hematology/Oncology
January 12, 2018
10.1097/mph.0000000000001062
Cited by 15

Related Papers

A randomized comparison of nativeEscherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study
|Blood|2002|496
Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group
|Blood|2003|361
Comparison of Autologous and Allogeneic Bone Marrow Transplantation for Treatment of High-Risk Refractory Acute Lymphoblastic Leukemia
|New England Journal of Medicine|1987|334
The genomic landscape of juvenile myelomonocytic leukemia
|Nature Genetics|2015|310
Juvenile xanthogranuloma: Forms of systemic disease and their clinical implications
|The Journal of Pediatrics|1996|294